We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
-15.01%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$461M
AUM Growth
-$222M
Cap. Flow
-$108M
Cap. Flow %
-23.46%
Top 10 Hldgs %
59.88%
Holding
143
New
25
Increased
20
Reduced
27
Closed
54

Top Buys

Rank Stock Value
1
SHPG
Shire pic
SHPG
+$24.9M
2
VTRS icon
Viatris
VTRS
+$13.9M
3
ITRN icon
Ituran Location and Control
ITRN
+$8.4M
4
PFE icon
Pfizer
PFE
+$7.53M
5
GOOGL icon
Alphabet (Google) Class A
GOOGL
+$4.18M

Top Sells

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$21.4M
2
BMY icon
Bristol-Myers Squibb
BMY
+$8.36M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$6.09M
4
GOOG icon
Alphabet (Google) Class C
GOOG
+$5.76M
5
INCY icon
Incyte
INCY
+$5.6M

Sector Composition

Rank Sector Weight
1 Healthcare 62.23%
2 Technology 3.77%
3 Utilities 2.89%
4 Communication Services 2.27%
5 Financials 1.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SGEN
126
DELISTED
Seagen Inc. Common Stock
SGEN
– –
-70,000
Closed -$3.14M
BLCM
127
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
– –
-23,152
Closed -$4.69M
CNCE
128
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
– –
-180,000
Closed -$3.42M
XLRN
129
DELISTED
Acceleron Pharma
XLRN
– –
-60,000
Closed -$2.93M
GWPH
130
CALL
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
– –
-50,000
Closed -$3.47M
GWPH
131
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
– –
-23,790
Closed -$1.65M
CEL
132
DELISTED
Cellcom Israel, Ltd.
CEL
– –
-212,300
Closed -$5.14M
NBRV
133
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
– –
-630
Closed -$1.5M
MDCO
134
DELISTED
Medicines Co
MDCO
– –
-60,000
Closed -$2.24M
ARRY
135
DELISTED
Array Biopharma Inc
ARRY
– –
-215,000
Closed -$907K
LOXO
136
DELISTED
Loxo Oncology, Inc
LOXO
– –
-45,000
Closed -$1.28M
TSRO
137
DELISTED
TESARO, Inc.
TSRO
– –
-30,686
Closed -$1.6M
VTAE
138
DELISTED
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
– –
-120,000
Closed -$2.17M
BITI
139
DELISTED
BIOTIE THERAPIES CORP SPONSORED ADR
BITI
– –
-193,646
Closed -$2.74M
EZCH
140
DELISTED
EZCHIP SEMICONDUCTOR LIMITED ORD SHS (IL)
EZCH
– –
-20,447
Closed -$505K
DMTX
141
DELISTED
Dimension Therapeutics, Inc
DMTX
– –
-200,000
Closed -$2.26M
GNVC
142
DELISTED
GenVec, Inc.
GNVC
– –
-18,650
Closed -$343K
ANAC
143
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
– –
-30,000
Closed -$3.39M
2 3 4 5
6

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q1 2016 Portfolio in Review

As of Q1 2016, Sphera Funds Management held 143 positions worth $461M, down 32% from $683M the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Sphera Funds Management withdrew a net $108M in Q1 2016, closing 54 positions and reducing 27 holdings. Its most notable exit was AbbVie, an estimated $21.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 62% of assets, up from 61% a quarter earlier, followed by Technology and Utilities.

Against the trend, Sphera Funds Management opened a new position in Viatris worth $13.3M.

  • Sphera Funds Management's largest Q1 2016 buy was Viatris: 287,827 shares worth $13.3M.
  • Sphera Funds Management added most to Shire pic in Q1 2016, an estimated $24.9M increase.
  • Sphera Funds Management's biggest Q1 2016 reduction was Celgene Corp, cutting an estimated $4.86M.
  • Sphera Funds Management fully exited AbbVie in Q1 2016, selling an estimated $21.4M.
  • Sphera Funds Management's ten largest holdings make up 60% of its $461M portfolio in Q1 2016.
  • Sphera Funds Management opened 25 new positions and closed 54 in Q1 2016.
  • Sphera Funds Management's portfolio value fell 32% quarter-over-quarter to $461M.

Based on Sphera Funds Management's 13F filing for Q1 2016, filed 16 May 2016.